Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

PMN-MDSC are a new target to rescue graft-versus-leukemia activity of NK cells in haplo-HSC transplantation.

Tumino N, Besi F, Di Pace AL, Mariotti FR, Merli P, Li Pira G, Galaverna F, Pitisci A, Ingegnere T, Pelosi A, Quatrini L, Munari E, Locatelli F, Moretta L, Vacca P.

Leukemia. 2019 Oct 4. doi: 10.1038/s41375-019-0585-7. [Epub ahead of print] No abstract available.

PMID:
31586150
2.

Role of interferon-γ in immune-mediated graft failure after allogeneic hematopoietic stem cell transplantation.

Merli P, Caruana I, De Vito R, Strocchio L, Weber G, Bufalo FD, Buatois V, Montanari P, Cefalo MG, Pitisci A, Algeri M, Galaverna F, Quintarelli C, Cirillo V, Pagliara D, Ferlin W, Ballabio M, De Min C, Locatelli F.

Haematologica. 2019 Nov;104(11):2314-2323. doi: 10.3324/haematol.2019.216101. Epub 2019 Feb 21.

3.

Current and future role of bispecific T-cell engagers in pediatric acute lymphoblastic leukemia.

Algeri M, Del Bufalo F, Galaverna F, Locatelli F.

Expert Rev Hematol. 2018 Dec;11(12):945-956. doi: 10.1080/17474086.2018.1540928. Epub 2018 Nov 8. Review.

PMID:
30358451
4.

Myelodysplastic syndromes in children.

Galaverna F, Ruggeri A, Locatelli F.

Curr Opin Oncol. 2018 Nov;30(6):402-408. doi: 10.1097/CCO.0000000000000488. Review.

PMID:
30222640
5.

De-Escalation and Discontinuation of Empirical Antibiotic Treatment in a Cohort of Allogeneic Hematopoietic Stem Cell Transplantation Recipients during the Pre-Engraftment Period.

Gustinetti G, Raiola AM, Varaldo R, Galaverna F, Gualandi F, Del Bono V, Bacigalupo A, Angelucci E, Viscoli C, Mikulska M.

Biol Blood Marrow Transplant. 2018 Aug;24(8):1721-1726. doi: 10.1016/j.bbmt.2018.03.018. Epub 2018 Mar 22.

6.

Imatinib mesylate-induced cardiomyopathy involves resident cardiac progenitors.

Savi M, Frati C, Cavalli S, Graiani G, Galati S, Buschini A, Madeddu D, Falco A, Prezioso L, Mazzaschi G, Galaverna F, Lagrasta CAM, Corradini E, De Angelis A, Cappetta D, Berrino L, Aversa F, Quaini F, Urbanek K.

Pharmacol Res. 2018 Jan;127:15-25. doi: 10.1016/j.phrs.2017.09.020. Epub 2017 Sep 28.

PMID:
28964914
7.

Pre-Engraftment Bloodstream Infections after Allogeneic Hematopoietic Cell Transplantation: Impact of T Cell-Replete Transplantation from a Haploidentical Donor.

Mikulska M, Raiola AM, Galaverna F, Balletto E, Borghesi ML, Varaldo R, Gualandi F, Giannoni L, Pastori G, Giacobbe DR, Signori A, Del Bono V, Viscoli C, Bacigalupo A, Angelucci E.

Biol Blood Marrow Transplant. 2018 Jan;24(1):109-118. doi: 10.1016/j.bbmt.2017.08.024. Epub 2017 Aug 30.

8.

Combining flow cytometry and WT1 assessment improves the prognostic value of pre-transplant minimal residual disease in acute myeloid leukemia.

Guolo F, Minetto P, Clavio M, Miglino M, Galaverna F, Raiola AM, Di Grazia C, Colombo N, Pozzi S, Ibatici A, Bagnasco S, Guardo D, Kunkl A, Ballerini F, Ghiggi C, Lemoli RM, Gobbi M, Bacigalupo A.

Haematologica. 2017 Sep;102(9):e348-e351. doi: 10.3324/haematol.2017.167254. Epub 2017 May 11. No abstract available.

9.

Immunity to Infections after Haploidentical Hematopoietic Stem Cell Transplantation.

Aversa F, Prezioso L, Manfra I, Galaverna F, Spolzino A, Monti A.

Mediterr J Hematol Infect Dis. 2016 Oct 25;8(1):e2016057. eCollection 2016. Review.

10.

Wilms Tumor 1 Expression and Pre-emptive Immunotherapy in Patients with Acute Myeloid Leukemia Undergoing an Allogeneic Hemopoietic Stem Cell Transplantation.

Di Grazia C, Pozzi S, Geroldi S, Grasso R, Miglino M, Colombo N, Tedone E, Luchetti S, Lamparelli T, Gualandi F, Ibatici A, Bregante S, Van Lint MT, Raiola AM, Dominietto A, Varaldo R, Galaverna F, Ghiso A, Sica S, Bacigalupo A.

Biol Blood Marrow Transplant. 2016 Jul;22(7):1242-1246. doi: 10.1016/j.bbmt.2016.03.005. Epub 2016 Mar 10.

11.

Improved Outcome of Alternative Donor Transplantations in Patients with Myelofibrosis: From Unrelated to Haploidentical Family Donors.

Bregante S, Dominietto A, Ghiso A, Raiola AM, Gualandi F, Varaldo R, Di Grazia C, Lamparelli T, Luchetti S, Geroldi S, Casarino L, Pozzi S, Tedone E, Van Lint MT, Galaverna F, Barosi G, Bacigalupo A.

Biol Blood Marrow Transplant. 2016 Feb;22(2):324-329. doi: 10.1016/j.bbmt.2015.09.028. Epub 2015 Oct 9.

12.

Cardioprotection by Targeting the Pool of Resident and Extracardiac Progenitors.

Urbanek K, Frati C, Graiani G, Madeddu D, Falco A, Cavalli S, Lorusso B, Gervasi A, Prezioso L, Savi M, Ferraro F, Galaverna F, Rossetti P, Lagrasta CA, Re F, Quaini E, Rossi F, Angelis AD, Quaini F.

Curr Drug Targets. 2015;16(8):884-94. Review.

PMID:
25619752
13.

DLI after haploidentical BMT with post-transplant CY.

Ghiso A, Raiola AM, Gualandi F, Dominietto A, Varaldo R, Van Lint MT, Bregante S, Di Grazia C, Lamparelli T, Galaverna F, Stasia A, Luchetti S, Geroldi S, Grasso R, Colombo N, Bacigalupo A.

Bone Marrow Transplant. 2015 Jan;50(1):56-61. doi: 10.1038/bmt.2014.217. Epub 2014 Oct 13.

PMID:
25310304
14.

Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia.

De Astis E, Clavio M, Raiola AM, Ghiso A, Guolo F, Minetto P, Galaverna F, Miglino M, Di Grazia C, Ballerini F, Marani C, Pastori G, Mitscheunig L, Cruciani F, Lovera D, Varaldo R, Ghiggi C, Lemoli RM, Bacigalupo A, Gobbi M.

Ann Hematol. 2014 Dec;93(12):2011-8. doi: 10.1007/s00277-014-2143-8. Epub 2014 Jul 4.

PMID:
24989345
15.

Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts.

Raiola AM, Dominietto A, di Grazia C, Lamparelli T, Gualandi F, Ibatici A, Bregante S, Van Lint MT, Varaldo R, Ghiso A, Gobbi M, Carella AM, Signori A, Galaverna F, Bacigalupo A.

Biol Blood Marrow Transplant. 2014 Oct;20(10):1573-9. doi: 10.1016/j.bbmt.2014.05.029. Epub 2014 Jun 5.

16.

CD34 selected cells for the treatment of poor graft function after allogeneic stem cell transplantation.

Stasia A, Ghiso A, Galaverna F, Raiola AM, Gualandi F, Luchetti S, Pozzi S, Varaldo R, Lamparelli T, Bregante S, Van Lint MT, di Grazia C, Bacigalupo A.

Biol Blood Marrow Transplant. 2014 Sep;20(9):1440-3. doi: 10.1016/j.bbmt.2014.05.016. Epub 2014 May 24.

17.

Unmanipulated haploidentical BMT following non-myeloablative conditioning and post-transplantation CY for advanced Hodgkin's lymphoma.

Raiola A, Dominietto A, Varaldo R, Ghiso A, Galaverna F, Bramanti S, Todisco E, Sarina B, Giordano L, Ibatici A, Santoro A, Clavio M, Bacigalupo A, Castagna L.

Bone Marrow Transplant. 2014 Feb;49(2):190-4. doi: 10.1038/bmt.2013.166. Epub 2013 Nov 4.

PMID:
24185585
18.

Management of early stage chronic myeloid leukemia: state-of-the-art approach and future perspectives.

Galaverna F, Ghiggi C, Guolo F, Beltrami G, Dellepiane C, Giannoni L, Carella A, Carella AM.

Curr Cancer Drug Targets. 2013 Sep;13(7):749-54. Review.

PMID:
23952099
19.

Cancer treatment-induced cardiotoxicity: a cardiac stem cell disease?

Prezioso L, Tanzi S, Galaverna F, Frati C, Testa B, Savi M, Graiani G, Lagrasta C, Cavalli S, Galati S, Madeddu D, Lodi Rizzini E, Ferraro F, Musso E, Stilli D, Urbanek K, Piegari E, De Angelis A, Maseri A, Rossi F, Quaini E, Quaini F.

Cardiovasc Hematol Agents Med Chem. 2010 Jan;8(1):55-75. Review.

PMID:
20210776

Supplemental Content

Loading ...
Support Center